Major Depressive Disorder - Japan Drug Forecast and Market Assessment to 2025
Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly’s Cymbalta and Otsuka/BMS’ Abilify have occurred, and recent launches of Lundbeck/Takeda’s Trintellix and Otsuka/Lundbeck’s Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.
GlobalData estimated that MDD drug sales in Japan during 2015 reached $315.0m, making it the second largest single market in the 7MM. GlobalData estimates that the Japanese MDD market will be turbulent during the forecast period with important patent losses occurring, such as Otsuka/BMS’ Abilify, Eli Lilly’s Cymbalta, and Lundbeck/Allergan’s Lexapro. Effexor will see the highest growth rate of any drug in the Japanese MDD market over the 10-year forecast.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the purchase.
- Overview of MDD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in Japan including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in Japan from 2015-2025. - Analysis of the impact of key events as well the drivers and restraints affecting Japan MDD market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for MDD. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2015-2025 in Japan.
Our reports have been used by over 10K customers, including:
Scope of the Report The report titled “Global Psychedelic Drugs Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)”, provides an in depth analysis of the global psychedelic drugs market by value, by indication, etc. The report also provides a detailed analysis of the COVID-19 impact on the psychedelic...
190 pages •
By Global Industry Analysts
• Apr 2021
- Global Mental Health and Intellectual Disability Facilities Market to Reach $239.6 Billion by 2027
- Amid the COVID-19 crisis, the global market for Mental Health and Intellectual Disability Facilities estimated at US$172.9 Billion in the year 2020, is projected to reach a revised size of US$239.6 Billion...
Metabotropic Glutamate Receptor 2 - Pipeline Review, H1 2020
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes....
This report is 80% complete and can be delivered within three working days post order confirmation and will include the latest impact analysis of Covid-19 in 2020 and forecast. Global Behavioral Rehabilitation Market By Application (Anxiety Disorder, Mood Disorder, Substance Abuse Disorder, Personality Disorder, Attention...
Road to recovery: Growing demand for and acceptance of industry services will boost revenue Abstract Mental Health & Substance Abuse Centres in Canada The rising awareness and acceptance of mental health and substance abuse illnesses have contributed to revenue growth for the Mental Health and Substance...
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H2 2018 Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation...
Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Autism Spectrum Disorders in 22 Major Markets Autism Spectrum Disorders (ASD) or Pervasive Developmental Disorder (PDD) defines a group of developmental disability disorders. These disorders include: Autism, Pervasive Developmental Disorder not otherwise specified (PDD-NOS), Asperger...
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Pipeline Review, H1 2018 Summary Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation...
Health Provider Density
Prescription Drug Sales
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.